Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome
Authors:
- 1 May 2017
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 153, 90-94
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAsPLOS ONE, 2013
- Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndromeAutoimmunity Reviews, 2012
- Autoantibodies Directed Against Domain I of Beta2-Glycoprotein ICurrent Rheumatology Reports, 2010
- Clinical course of high‐risk patients diagnosed with antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- Update of the guidelines for lupus anticoagulant detectionJournal of Thrombosis and Haemostasis, 2009
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Antibody profiles for the diagnosis of antiphospholipid syndromeThrombosis and Haemostasis, 2005
- β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndromeBlood, 2004
- β2-Glycoprotein I, the playmaker of the antiphospholipid syndromeClinical Immunology, 2004
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982